Greater Access to Fertility Medication
Senate Bill 572 would expand access to fertility medication in North Carolina for health benefit plans that already cover fertility treatment and for the State Health Plan for teachers and state employees. For private health benefit plans, the bill requires that if an insurer covers any fertility treatment, then coverage limits for ovulation medication must be treated the same as limits on other prescription drugs, and annual or lifetime caps may not be applied to ovulation medication or ovulation induction cycles when services are provided by in-network providers. The bill also clarifies that it does not require a plan to cover fertility treatment in the first place, and it does not mandate coverage for experimental fertility procedures.
For the State Health Plan, the bill directs the Board of Trustees to remove annual and lifetime limits on ovulation medication and ovulation induction cycles beginning with the January 1, 2026 plan year, again only for in-network services. It also requires that any limits on ovulation medication not be more restrictive than limits on other prescription medications. The bill appropriates recurring General Fund money to the Department of State Treasurer to cover the State Health Plan’s increased costs: $300,000 for fiscal year 2025-26 and $600,000 for fiscal year 2026-27.
The bill’s impact would be to amend North Carolina insurance law in Chapter 58 and to impose a new coverage requirement on the State Health Plan. It would affect insurers offering fertility treatment coverage, the State Health Plan, the Department of State Treasurer, and individuals seeking fertility-related medications and ovulation induction services. The measure is prospective, applying to insurance contracts issued, renewed, or amended on or after October 1, 2025, and to the State Health Plan beginning in 2026.
Because there are no committee transcripts or recorded votes provided, the available context does not show a documented floor debate or vote pattern. Based on the bill text and title, the general sentiment appears supportive of expanding fertility medication access and reducing coverage barriers, while still preserving insurer discretion not to offer fertility coverage at all. The main policy tension is likely the cost and mandate implications for insurers and the State Health Plan versus the goal of improving access for patients pursuing fertility treatment.
The bill would add a new section to Chapter 58 governing fertility treatment coverage and would require parity in how ovulation medication is covered when a health benefit plan already covers fertility treatment. It would also eliminate annual and lifetime caps on ovulation medication and ovulation induction cycles for in-network services under the State Health Plan, while appropriating recurring funds to offset the plan’s added costs. The affected parties include insurers, the State Health Plan, the Department of State Treasurer, and covered individuals seeking fertility-related care.
No committee discussion or vote record was provided, so there is no direct evidence of legislative debate or recorded support/opposition. From the bill’s structure and title, the measure appears intended to improve access to fertility medication and is likely to be viewed favorably by advocates for reproductive and family-building care. At the same time, the inclusion of cost estimates and the preservation of insurer discretion not to cover fertility treatment suggest awareness of fiscal and coverage concerns.
The likely points of contention are whether the bill creates an expensive coverage mandate and whether insurers or the State Health Plan should bear the cost of removing medication and cycle limits. Supporters would likely emphasize access, fairness, and treatment continuity for patients using fertility care, while opponents or skeptics may focus on premium impacts, state spending, and the distinction between requiring parity in coverage limits versus requiring fertility coverage itself. The bill also draws a line excluding experimental procedures, which may reduce controversy over scope but leaves open questions about what treatments qualify as established fertility care.